

Linking Patients to Protocols: An Automated Registry Communication System

Rachel Richesson, PhD, MPH University of South Florida College of Medicine

> 5th International Conference on Rare Diseases and Orphan Drugs Istituto Superiore di Sanità, Rome February 23-25, 2009



Where

Welcome! You have reached the home page for the Rare Diseases Clinical Research Network (RDCRN). Each Consortium within the network provides detailed information on several rare diseases.

What if I am unsure of which consortium to visit?

Scan the list to the right for a disease name. Once you have located it, click on the link for a brief description which will lead you to the correct consortium.

How will this consortium be useful to me?

You can take action! Once you have reached the correct consortium, you will be able to join the contact registry for clinical research trials. You will also find several helpful resources that include participating clinical center information, support and advocacy group information and other useful links.



RDCRN Consortium Studies are opening!

Learn More >>

Last Updated: 11 May 2008

Look here for information on open studies and future studies

Clinical Research Consortia:

Urea Cycle Disorders Consortium [Study Information]

- [nformation]
 N-Acetylqlutamate Synthase (NAGS) Deficiency
- Carbamyl Phosphate Synthetase (CPS) Deficiency
- Ornithine Transcarbamylase (OTC) Deficiency
- Argininosuccinate Synthetase Deficiency (Citrullinemia I)
- Citrin Deficiency (Citrullinemia II)
- Argininosuccinate Lyase Deficiency (Argininosuccinic Aciduria)
- Arginase Deficiency (Hyperargininemia)
- Ornithine Translocase Deficiency (HHH) Syndrome

Angelman, Rett, and Prader-Willi Syndromes Consortium [Study Information]

- Angelman Syndrome
- Rett Syndrome
- Prader-Willi Syndrome

CINCH - Consortium for Clinical Investigation of Neurological Channelopathies [Study Information]

Yasculitis Clinical Research Consortium [Study Information]

- Wegener's Granulomatosis (WG)
 - Microscopic Polyangiitis (MPA)
 - Churg-Strauss Syndrome (CSS)
- Polyarteritis Nodosa (PAN)
- Takayasu's Arteritis (TAK)
- Giant Cell (Temporal) Arteritis (GCA)

Rare Genetic Steroid Disorders Consortium [Study Information]

- Congenital Adrenal Hyperplasia
- Androgen Receptor Defects
- Apparent Mineralocorticoid Excess (Low Renin Hypertension)


Rare Thrombotic Diseases Consortium [Study Information]

- Antiphospholipid Antibody Syndromes (APS)
- Heparin-induced Thrombocytopenia (HIT)



Consortium Website


• The consortium-specific public website provides the public with detailed information about the consortium and how to join the contact registry.





Consortium Registry Links

• The public consortium website contains a "join the registry" page that provides links to the registry for each disorder.





Registry Description

Description and Purpose of the Rare Diseases Clinical Research Network (RDCRN) Contact Registry

Thank you for your interest in this contact registry. The purpose of this contact registry is to provide an opportunity for individuals with a specific rare disease or disorder to register themselves to receive information about studies conducted by the Rare Diseases Clinical Research Network, You may also learn about progress being made towards treatment advances by researchers who specialize in your disease or disorder.

By joining the Contact Registry, you will be asked to provide information about you (or your child) and how you can be contacted. The registry will use that information to contact individuals who might qualify for participation in a research study. We may also use your contact information in order to communicate treatment information and sources.

Because of their rarity, researchers often have difficulty finding enough patients to study these diseases in order to understand and cure them.

To learn more about the Contact Registry and how it functions, click "Learn More",

To join the contact registry, click "Join Contact Registry" and give authorization and complete the contact registry form.

If you are currently a member of the Contact Registry and would like to discontinue enrollment or update your contact information, click "Update Info".

Learn More

Join Contact Registry

Update Info

Close Window



Learn More


• A "learn more" page has in depth material pertaining to the contact registry.





Authorization Agreement

• Registrants must agree to the HIPAA compliant authorization in order to register with the contact registry.






Registry Form

- The registration form contains information such as disorder, date of diagnosis, etc.
- The registrant enters their information into the web based form and registers with the Contact Registry.





Registry Acknowledgement Box




RAREDISEASES



Registry Acknowledgement Email


- An acknowledge Email is sent to the registrant after they register or if they update their information.
- The registrant is provided with links in the Email to update their information.





Sample Study Email

- Emails can be sent to registrants by automations, schedules, or manually.
- The Emails can be customized to include content from each Consortium.
- A template is created to improve Email efficiency and quality.





Sample Study Email











Automated Communications

- Typical automations:
 - Welcome
 - New Study
 - New Clinical Site
 - Periodic (every 6 months)
- Automations can be customized by study or consortium

Administrator Interface: Campaign Manager




Administrator Interface: Campaign Configuration



Administrator Interface: Registrant Information and Updates









Consortia	N
Angelman, Rett, & Prader-Willi Syndromes	791
Bone Marrow Failure Disease	387
Cholestatic Liver Disease	290
Neurologic Channelopathies	178
Genetic Diseases of Mucociliary Clearance	276
Genetic Steroid Disorders	60
Rare Lung Disease	262
Rare Thrombotic Disease	463
Urea Cycle Disorders	281
Vasculitis	1899
Total	4887




Preferred Contact Method


Contact Method	N	Percent
Email	3500	72%
Phone	715	15%
Mail	607	12%
Fax	12	0%
Missing	53	1%
RA	4887	100%




Reported Referral Method

How did you find out about us?	N	Percent
Internet	2119	45%
Media	7	0%
Medical Professional	410	8%
Missing	29	1%
Other	112	2%
Publication	146	3%
Support Group or Foundation	1867	38%
Word of mouth	97	2%
	4887	100%











Contact Registry's Global Reach



- •10-15% of the Contact Registry have non-US, non-Canada Addresses
- Over 60 countries represented



Country	N	%
Missing	22	0.52
United States	3593	85.45
American Samoa	1	0.02
Argentina	9	0.21
Australia	70	1.66
Austria	2	0.05
Bahamas	1	0.02
Belgium	2	0.05
Bolivia	2	0.05
Brazi1	11	0.26
Bulgaria	1	0.02
Cameroon	1	0.02
Canada	177	4.21
Chile	3	0.07
China	2	0.05
Colombia	2	0.05
Costa Rica	1	0.02
Croatia	3	0.07
Cuba	1	0.02
Cyprus	1	0.02
Denmark	2	0.05
Egypt	2	0.05
El Salvador	3	0.07
Estonia	1	0.02
Finland	3	0.07

	Country	N	%
	France	3	0.07
	Germany	12	0.29
	Greece	1	0.02
	Guatemala	1	0.02
	Hong Kong	1	0.02
	Hungary	1	0.02
	Iceland	1	0.02
	India	22	0.52
	Indonesia	1	0.02
	Iran	1	0.02
	Ireland	11	0.26
	Israel	5	0.12
-	Italy	7	0.17
	Japan	4	0.10
	Kenya	1	0.02
	Kuwait	1	0.02
	Luxembourg	1	0.02
	Malaysia	2	0.05
	Malta	1	0.02
	Mexico	7	0.17
	Nepal	1	0.02
	Netherlands	10	0.24
	New Zealand	12	0.29
1	Norway	1	0.02
J	Peru	1	0.02

Country	N	%
Philippines	2	0.05
Poland	4	0.10
Portugal	4	0.10
Puerto Rico	2	0.05
Romania	2	0.05
Russia	1	0.02
Singapore	4	0.10
South Africa	13	0.31
Spain	8	0.19
Sweden	5	0.12
Switzerland	3	0.07
Taiwan	2	0.05
Thailand	5	0.12
Trinidad And Tobago	1	0.02
Turkey	3	0.07
Ukraine	1	0.02
United Arab Emirates	1	0.02
United Kingdom	119	2.83
	4205	100.00



Enrollment on Clinical Studies

		Within 200 miles of a clinical site	Within 100 miles of a clinical site
Clinical Research Consortium	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)	Total # of Contact Registrants Eligible for Studies (% enrolled in selected studies)
Angelman, Rett, & Prader-Willi	648 (15%)	213 (20%)	98 (29%)
Bone Marrow Failures	282 (7%)	96 (13%)	46 (17%)
Genetic Diseases of Mucociliary Clearance	315 (27%)	52 (42%)	32 (28%)
Urea Cycle Disorders	207 (27%)	97 (37%)	68 (43%)
Vasculitis	1325 (6%)	482 (8%)	229 (12%)
All sampled studies (12, 2/23/2006)	2777 (12%)	940 (16%)	473 (21%)



Summary

- Effective
- Patient-driven
- Automated
- Scalable






Future Directions

- Expand types of data collected
 - Define registry vs. (research) study?
- Additional diseases
- Additional sources for research studies
- Support community-based research





Acknowledgements

- NIH Office of Rare Diseases (ORD)
- NIH National Center for Research Resources (NCRR)
- RDCRN Coalition of Patient Advocacy Groups (CPAG)

- Ken Young
- Jennifer Lloyd

Supported by Grant # RR019259 from the NCRR, an NIH component, and the Office of Rare Diseases. Contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or ORD or NIH.



Questions

Jeffrey Krischer, PhD

Jeffrey.Krischer@epi.usf.edu

Rachel Richesson, PhD, MPH Rachel.Richesson@epi.usf.edu

RAREDIS